Metraipolis › archive › dc_0b2bec2374c8

Impact of concurrent systemic and inhaled corticosteroid use on clinical outcomes in advanced lung cancer patients receiving immune checkpoint inhibitors — Europe PMC PMID:41549296

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41549296
DOI
10.1186/s12931-[numero omesso]-5
License (as archived)
solo-consultazione
Archived
2026-11-06T17:24:43.657Z
SHA-256 of the archived text
f715b771386e9682ac7265cffe0b5138864a280a051f3ac4e59e2b7f5bb5e1ba
Stable URL of this page
https://metraipolis.com/documento/dc_0b2bec2374c8

How to cite

Impact of concurrent systemic and inhaled corticosteroid use on clinical outcomes in advanced lung cancer patients receiving immune checkpoint inhibitors — Europe PMC PMID:41549296 — Europe PMC (en), https://europepmc.org/article/MED/41549296 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0b2bec2374c8 (Metraipolis archive dc_0b2bec2374c8, sha256 f715b771386e9682ac7265cffe0b5138864a280a051f3ac4e59e2b7f5bb5e1ba)
BibTeX
@misc{dc0b2bec2374c8,
  title = {Impact of concurrent systemic and inhaled corticosteroid use on clinical outcomes in advanced lung cancer patients receiving immune checkpoint inhibitors — Europe PMC PMID:41549296},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41549296},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0b2bec2374c8; sha256 f715b771386e9682ac7265cffe0b5138864a280a051f3ac4e59e2b7f5bb5e1ba},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41549296. Agents can read the archived copy with the MCP tool read_document.